Welcome to our dedicated page for RAPT Therapeutics SEC filings (Ticker: RAPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
RAPT Therapeutics, Inc. filings document the regulatory record of a clinical-stage immunology biopharmaceutical company and its transition from a Nasdaq-listed issuer to a wholly owned subsidiary of GlaxoSmithKline LLC. The record includes Form 8-K disclosures for operating and financial results, Regulation FD presentation materials, material agreements, capital-structure matters, and shareholder-related transaction disclosures.
Later filings include a Form 25 for removal of RAPT common stock from Nasdaq listing and registration, and a Form 15 covering termination of registration or suspension of reporting duties for its common stock. These documents record the completed merger, the surviving-company structure, the delisting process, and Exchange Act reporting-status changes.
RAPT Therapeutics launched a primary offering of 8,333,334 shares of common stock at $30.00 per share. Underwriters have a 30‑day option to purchase up to 1,250,000 additional shares at the public price, less discounts.
Gross proceeds are $250,000,020 with underwriting discounts of $15,000,001, yielding proceeds to the company before expenses of $235,000,019. RAPT estimates net proceeds of approximately $234.4 million (or $269.7 million if the option is fully exercised). The company intends to use the funds to advance RPT904 in food allergies and chronic spontaneous urticaria, support other pipeline programs, and for working capital and general corporate purposes. Based on current plans, cash including these proceeds is expected to fund operations into 2028.
Shares outstanding were 16,536,069 as of June 30, 2025; this is a baseline figure, not the amount being offered.
RAPT Therapeutics (RAPT) launched a primary offering of common stock via a preliminary prospectus supplement under its Form S-3 shelf. The filing includes a 30-day option for underwriters to purchase additional shares at the public offering price, less underwriting discounts and commissions. RAPT’s stock trades on Nasdaq as “RAPT”; the last reported sale price was $33.67 per share on October 20, 2025.
RAPT intends to use net proceeds, together with existing cash, to advance RPT904 in food allergies and chronic spontaneous urticaria (CSU), support other pipeline initiatives, and for working capital and general corporate purposes. Shares outstanding were 16,536,069 as of June 30, 2025.
RAPT and Jeyou reported positive topline Phase 2 CSU data for RPT904, showing numerically greater UAS7 improvements and higher UAS7=0 rates at Weeks 8, 12 and 16 versus omalizumab, with no serious adverse events related to study drug and no treatment-related discontinuations. The companies plan to discuss Phase 3 development with regulators and to initiate a Phase 2b trial in food allergies before the end of 2025.
RAPT Therapeutics, Inc. has a Schedule 13G disclosure showing Nantahala Capital Management, LLC and its managing members, Wilmot B. Harkey and Daniel Mack, beneficially own 951,613 shares of RAPT common stock, representing 5.75% of the outstanding class. The filing states these shares are held by funds and separately managed accounts under Nantahala's control and that none of the Reporting Persons possess sole voting or dispositive power; all voting and dispositive power is shared. The statement affirms the position was acquired and is held in the ordinary course of business and not for the purpose of influencing control of the issuer.
RAPT Therapeutics, Inc. Schedule 13G/A filed by Redmile Group, LLC, Jeremy C. Green and Redmile Biopharma Investments III, L.P. reports beneficial ownership tied to both directly held common stock and exercisable warrants. Redmile Group and Mr. Green report 1,765,303 shares beneficially owned (9.9% of the class) and RBI III reports 1,147,390 shares (6.5% of the class). The filings explain ownership counts after a 1-for-8 reverse stock split and include up to 1,134,617 shares that could be issued upon exercise of certain pre-funded warrants subject to a 9.99% beneficial ownership blocker.
The filing discloses that Redmile Group acts as investment manager to Redmile Funds and that Mr. Green may be deemed to beneficially own the reported securities as principal of Redmile Group. Each reporting person disclaims beneficial ownership except for any pecuniary interest. The statement certifies the holdings are not for the purpose of changing control.
RAPT Therapeutics director Scott Braunstein received a stock option grant on June 21, 2025, as reported in this Form 4 filing. The derivative securities transaction details include:
- Grant of 25,000 stock options to purchase common stock
- Exercise price set at $7.43 per share
- Options expire on June 21, 2035
- Vesting schedule: Equal annual installments over three years from grant date
This equity compensation grant appears to be part of the company's standard director compensation program. The options were granted with direct ownership form, and the filing was submitted by attorney-in-fact Rodney Young on June 24, 2025. This transaction represents a new position for the director, as no prior holdings were reported in the filing.